Skip to main content
Top

19-09-2019 | Medications | Video | Article

Expert commentary: Trial results of imeglimin in type 2 diabetes

print
PRINT
insite
SEARCH

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

Receive weekly updates on the diabetes news that matters to you


Read the interview transcript

Back to the EASD 2019 conference hub

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content